{"id":"NCT04449861","sponsor":"AstraZeneca","briefTitle":"Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)","officialTitle":"An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-07","primaryCompletion":"2023-03-30","completion":"2023-03-30","firstPosted":"2020-06-29","resultsPosted":"2024-11-27","lastUpdate":"2024-11-27"},"enrollment":166,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Carcinoma Extensive Disease"],"interventions":[{"type":"DRUG","name":"Durvalumab plus chemotherapy","otherNames":[]}],"arms":[{"label":"Durvalumab plus 4-6 cycles chemotherapy","type":"EXPERIMENTAL"}],"summary":"This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.","primaryOutcome":{"measure":"Percentage of Participants With Grade â‰¥3 AEs","timeFrame":"19 months","effectByArm":[{"arm":"Durvalumab With EP","deltaMin":49.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419BR00018&amp;attachmentIdentifier=bea5d0f0-7872-4ddc-8841-04bef355afc5&amp;fileName=CSR_synophsis_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419BR00018&amp;attachmentIdentifier=8aab5cc6-2724-45a4-b01d-d43437179031&amp;fileName=Statistical_Analysis_Plan,_ANGEL.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419BR00018&amp;attachmentIdentifier=865699ee-8b5c-414d-8ad6-f245f3ac2534&amp;fileName=SCLC_treatment_study_China_CSP_v2.0_EN_clean_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":70,"n":165},"commonTop":["anaemia","nausea","vomiting","alopecia","constipation"]}}